Isis has a strong history of establishing corporate partnerships with pharmaceutical industry leaders. These collaborations provide funding to advance antisense drug discovery and clinical development programs, and to continuously enhance Isis' technologies. Collaborations also expand the practice of antisense technology, which may result in new drugs for patients in need and increased productivity of the pharmaceutical industry.

The Company's goal is to balance the use of corporate partner funding and equity sales to minimize dilution, and to retain significant product rights to enhance shareholder value. Throughout Isis’ history, the Company has been successful in generating corporate partner funding while both retaining control of its technology and delivering value to partners. These partnerships have produced products for Isis' and its partners' pipelines.

Isis has the ability to enter into a wide variety of partnership agreements focused on antisense research and therapeutics, functional genomics offerings, Ibis technologies, and intellectual property.